Abstract
ObjectiveDysfunction of human cavernous endothelial cells (HCECs) is a common pathological alteration caused by elevated high blood glucose levels associated with diabetes. To explore the protective effects of icariside II (ICA II) on HCECs, HCECs were isolated from non-diabetic human donors, cultured under high glucose (HG) conditions and treated with ICAII.MethodsThe cell apoptosis and proliferation, expression of Ki67 and Erk1/2, antioxidant capacity, and expression of Akt and eNOS were examined.ResultsChanges in cell apoptosis and proliferation indicated that HG treatment inhibited HCEC proliferation with lower percentage of Ki67-positive cells and lower expression and phosphorylation of Erk1/2. Furthermore, the total antioxidant capacity (T-AOC) of HCECs was reduced under HG conditions. In line with these findings, both expression and phosphorylation of Akt as well as eNOS was down regulated after HG treatment. The reduction in proliferative capacity, p-Erk1/2, p-Akt, and p-eNOS were partially prevented by ICA II in a concentration-dependent manner.ConclusionsThe protective effects of ICA II rescued HCEC from injury and dysfunction induced by HG in vitro. ICA II may be a candidate for prevention of the development of diabetic erectile dysfunction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.